Treatment of Reactive Arthritis with Axial Skeleton Involvement — Sacroiliitis or Spondylitis
Clinical scenario
This protocol applies to patients with reactive arthritis (ReA) whose disease has extended to involve the axial skeleton — presenting as sacroiliitis or, less frequently, cervical and thoracic spine involvement (spondylitis). This pattern of axial disease is a recognised subset of ReA and is seen more commonly in patients who are HLA-B27 positive.
Axial involvement — sacroiliitis or spinal disease — represents a distinct clinical subset of reactive arthritis that requires a specific therapeutic approach, separate from management of peripheral joint disease.
Treatment approach (partial overview)
For reactive arthritis with axial involvement, first-line management centres on anti-inflammatory therapy selected specifically for its suitability in axial disease. Notably, certain treatments that may benefit peripheral arthritis in ReA have been shown to have no significant effect on axial manifestations and are not recommended in this subset.
The structured regimen for this scenario specifies which class of anti-inflammatory agent is preferred and why — including which agents to avoid in axial disease.
Full protocol details, sequencing, and clinical decision logic are available via the link below.
References
- Axial skeleton involvement, usually a sacroiliitis or less frequently a cervical and thoracic spine involvement, is also common and is usually seen in patients HLA-B27 positive.
- Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line therapy in acute ReA.
- In patients with prevalent inflammatory back pain, drugs with long half-life such as naproxen are preferred.
- GCs have only limited value, if any, in axial manifestations of ReA. Consequently, they should not be used in this subset of the disease.
- It should be underlined that SSZ was effective only in patients with peripheral arthritis, without any significant effect on axial disease.
View source ↗